MELINTA THERAPEUTICS, INC. /NEW/ MLNT Cash Flow

Melinta therapeutics, inc. /new/ (MLNT)

CashFlow / TTM

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Mar'12
Operating activities
Net loss
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-44,600	-73,932	-95,243	-90,501	-90,666	-78,676	-86,850	-70,636	-62,043	-61,649	0	0	0	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	497	610	614	620	624	86	87	80	77	63	55	48	39	0	0	0	0
Non-cash interest expense
-	0	-22,949	-	-	-14,818	-9,890	-5,091	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Allocated Share-based Compensation Expense
944	3,299	3,402	3,465	8,863	7,743	6,833	6,450	-3,375	-1,445	722	2,515	4,876	3,964	2,715	1,785	0	0	0	-	-	-	-	-	-	-	-	-
Issuance of common shares for service
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Issuance of common shares for license agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Share-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	0
Change in fair value of warrant & conversion liabilities
-	-	-15,156	-	-	-	-24,475	-335	0	0	0	-	-	-	-	-	-	-	-	-120	0	0	0	-	-	-	-	-
Loss on disposal of assets
-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	0	0	231	-	597	735	733	767	0	0	0	-	-	-	-	-
Loss on extinguishment of debt
-3,038	-346	-346	-2,595	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reversal of loss contract
0	6,244	6,122	5,330	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Amortization of debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Changes in operating assets and liabilities:
Receivables
-19,971	-1,529	-8,417	5,044	17,532	2,484	6,385	3,140	10,136	7,390	6,373	-43	-3,628	-4,724	-15,433	228	-490	2,358	11,072	724	0	0	0	-	-	-	-	-
Inventory
4,923	13,973	18,632	17,541	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets and liabilities
2,072	-1,080	-1,922	-2,180	636	-485	1,871	-600	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	0	-1,277	-	-2,345	-1,172	748	2,980	3,396	2,452	1,125	142	0	0	0	0
Deposits
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	13	23	59	24	11	0	0	0	0
Accounts payable
-7,271	-7,248	-4,070	8,285	-790	-72	1,372	-1,269	4,386	-1,485	-236	-21	-3,003	165	-275	-2,874	4,157	4,351	2,064	5,620	0	0	0	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Accrued expenses
1,198	-1,837	-3,449	1,445	724	8,473	5,175	12,014	1,823	621	664	-1,840	-2,271	-2,435	-2,422	-2,418	648	372	62	611	399	-474	-536	49	0	0	0	0
Accrued interest on notes payable
174	-84	4,440	4,202	4,114	4,368	-154	110	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued payroll and benefits
-	-	-	-	-	-	-	-	-	-	-	-	0	0	487	-	662	374	150	553	578	390	201	438	0	0	0	0
Other non-current assets and liabilities
-3,442	1,497	-1,700	2,486	-1,078	-1,230	1,608	-157	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Investing activities
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-42,839	-70,580	-84,294	-77,103	-67,401	-72,554	-72,698	-55,559	-61,525	-49,092	0	0	0	-	-	-	-	-
IDB acquisition
-1	-1	-1	166,382	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of intangible assets
1,209	1,209	3,209	2,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
259	775	1,198	1,690	1,501	1,183	1,244	849	0	0	0	-	-	-	-	688	61	61	76	52	120	129	136	134	0	0	0	0
Proceeds from borrowing on convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Proceeds from borrowing on long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,238	0	0	0	0
Purchase of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Proceeds from sale of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net cash used in investing activities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Financing activities
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-688	-61	-61	-76	-52	0	0	0	-	-	-	-	-
Proceeds from the issuance of notes payable
0	0	0	111,421	110,265	120,265	142,255	38,844	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of convertible notes payable to related party
75,000	75,000	75,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Proceeds from issuance of common stock upon private placement, net of underwriting discounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Payment of share issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Costs associated with the issuance of notes payable
2,183	2,183	1,301	6,455	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	35	34	34	334	300	0	0	0	0
Proceeds from the issuance of warrants
0	0	0	33,264	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of royalty agreement
0	0	0	1,472	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of notes payable disbursement option
0	0	0	7,609	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-
Proceeds from Issuance of Common Stock
0	0	0	51,452	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net
8	-478	115,281	155,273	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt extinguishment
0	0	0	2,150	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IDB acquisition deferred payments
978	1,307	1,705	1,633	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options, net of cancellations
0	0	0	3	-4	-4	-4	88	-204	-173	-79	65	0	0	0	-	-	-	-	-	0	0	0	-	-	-	0	0
Proceeds from the issuance of convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Proceeds from issuance of common stock, net of underwriting discounts
-	-	-	-	-	-	-	-	-	-	-	-	0	0	94,000	-	0	0	0	-	-	-	-	54,407	0	0	0	0
Payment of preferred stock issuance costs
-	-	-	-	-	-	-	-	-	-	-	9	163	163	98	92	0	0	0	-	-	-	-	-	-	-	-	-
Principal payments on notes payable
0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-36,465	52,294	116,810	91,055	47,499	92,859	180,603	189,386	191,165	51,754	0	0	0	-	-	-	-	-
Net cash provided by financing activities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net decrease in cash and equivalents
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and equivalents
-	-	-	-	-	-	-	-	-	-	-79,876	-18,749	31,865	13,301	-20,544	19,617	107,844	133,765	129,563	2,610	-36,230	-52,989	19,402	26,394	0	0	0	0
Supplemental cash flow information:
Cash paid for interest
13,067	17,541	13,265	13,259	14,209	4,939	6,318	2,326	2,871	3,653	2,577	2,411	1,290	1,356	1,492	1,600	1,660	1,723	1,650	1,579	1,506	1,534	1,327	1,208	0	0	0	0
Supplemental disclosure of non-cash financing and investing activities:
Accrued purchases of fixed assets
0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued notes payable issuance costs
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of redeemable convertible preferred shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Beneficial conversion costs of Series B preferred shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Notes payable converted into Series A redeemable convertible preferred shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Allocation of the Class C proceeds to the Class C Purchase Option
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Conversion of the Class C Purchase Option
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Allocation of the convertible note proceeds to warrant
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Allocation of the long-term debt proceeds to warrant
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	461	0	0	0	0
Conversion of convertible notes payable and accrued interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Conversion of redeemable convertible preferred shares into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Reclassification of warrant liability to additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0